CATALOGO DEI PRODOTTI DELLA RICERCA

SENNA, Gianenrico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.426
EU - Europa 6.158
AS - Asia 4.992
SA - Sud America 753
AF - Africa 181
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 6
Totale 18.523
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.269
RU - Federazione Russa 2.976
SG - Singapore 2.211
CN - Cina 1.157
IT - Italia 969
GB - Regno Unito 615
BR - Brasile 575
VN - Vietnam 510
HK - Hong Kong 475
FR - Francia 330
DE - Germania 325
SE - Svezia 270
IE - Irlanda 263
KR - Corea 156
FI - Finlandia 142
IN - India 107
CA - Canada 78
JP - Giappone 68
AR - Argentina 60
MX - Messico 57
BD - Bangladesh 54
NL - Olanda 50
ZA - Sudafrica 43
ID - Indonesia 41
TR - Turchia 41
UA - Ucraina 40
ES - Italia 37
PL - Polonia 34
IQ - Iraq 32
NG - Nigeria 30
TG - Togo 27
BJ - Benin 25
CO - Colombia 24
AT - Austria 23
VE - Venezuela 23
EC - Ecuador 22
SA - Arabia Saudita 22
BE - Belgio 20
CL - Cile 20
MA - Marocco 15
PK - Pakistan 15
UZ - Uzbekistan 13
JO - Giordania 11
PY - Paraguay 11
LT - Lituania 10
AZ - Azerbaigian 9
KE - Kenya 9
PH - Filippine 9
NP - Nepal 8
AE - Emirati Arabi Uniti 7
CH - Svizzera 7
NO - Norvegia 7
PE - Perù 7
UY - Uruguay 7
AU - Australia 6
EG - Egitto 6
IL - Israele 6
MY - Malesia 6
CR - Costa Rica 5
DZ - Algeria 5
JM - Giamaica 5
KZ - Kazakistan 5
SN - Senegal 5
AL - Albania 4
BG - Bulgaria 4
CZ - Repubblica Ceca 4
LB - Libano 4
RO - Romania 4
TN - Tunisia 4
DO - Repubblica Dominicana 3
HU - Ungheria 3
KG - Kirghizistan 3
LV - Lettonia 3
OM - Oman 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BO - Bolivia 2
DM - Dominica 2
ET - Etiopia 2
EU - Europa 2
HN - Honduras 2
HR - Croazia 2
LK - Sri Lanka 2
MG - Madagascar 2
ML - Mali 2
PA - Panama 2
RS - Serbia 2
XK - ???statistics.table.value.countryCode.XK??? 2
YE - Yemen 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
Totale 18.504
Salva come PNG Salva come JPEG
Città #
Singapore 1.151
Moscow 1.001
Ashburn 909
San Jose 773
Dallas 719
Chandler 627
Hong Kong 466
Southend 422
Verona 311
New York 294
Dublin 258
Beijing 257
The Dalles 248
Jacksonville 158
Ho Chi Minh City 151
Woodbridge 145
Los Angeles 137
Hanoi 111
Lawrence 109
Princeton 109
Houston 90
Wilmington 90
Munich 89
Ann Arbor 75
Sindelfingen 74
Buffalo 71
Tokyo 61
Helsinki 60
Jinan 60
São Paulo 60
Milan 59
London 57
Redondo Beach 53
Shenyang 53
Columbus 47
Rome 41
Council Bluffs 39
Nanjing 39
Denver 38
Bologna 37
Redmond 37
Santa Clara 37
Chennai 36
Hebei 36
Boardman 35
Guangzhou 35
Johannesburg 32
Orem 32
Warsaw 30
Abuja 29
Haiphong 29
Montreal 29
Turku 29
Amsterdam 28
Brooklyn 28
Seattle 28
Redwood City 27
Changsha 26
Lomé 26
Ningbo 26
Poplar 26
Cotonou 25
Da Nang 25
Tianjin 25
Kent 23
Rio de Janeiro 23
Stockholm 23
Haikou 22
San Francisco 22
Nanchang 21
Norwalk 21
Toronto 21
Dong Ket 20
Frankfurt am Main 20
Naples 20
Nuremberg 20
Mumbai 19
Taizhou 19
Taiyuan 18
Atlanta 17
Brussels 17
Hangzhou 17
Zhengzhou 17
Mexico City 16
Phoenix 16
Boston 15
Chicago 15
Falkenstein 15
Jakarta 15
Manchester 14
Padova 14
Ankara 13
Baghdad 13
Tashkent 13
Seoul 12
Vienna 12
Curitiba 11
Florence 11
Lanzhou 11
Querétaro 11
Totale 10.872
Salva come PNG Salva come JPEG
Nome #
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management 434
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis 224
Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels 207
Fatal asthma; is it still an epidemic? 207
Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and hymenopteria allergy 202
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management 199
Safety of Biologic Therapies for Severe Asthma: An Analysis of Adverse Reactions Reported in the WHO Pharmacovigilance Database 197
Study on the Immunoreactivity of Triticum monococcum (Einkorn) Wheat in Patients with Wheat-Dependent Exercise-Induced Anaphylaxis for the Production of Hypoallergenic Foods 189
Allergic rhinitis: pharmacotherapy in pregnancy and old age 185
La salute del respiro: epidemiologia, costi sanitari ed implicazioni sociali delle malattie respiratorie croniche in Europa e in Italia 184
Asthmatic patients in COVID-19 outbreak: Few cases despite many cases 180
Allergy and the bone: unexpected relationships 176
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 175
Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience 171
Asthma control in primary care: the results of an observational cross-sectional study in Italy and Spain 169
Adverse reaction to local anaesthetics: Is it always allergy? 167
Analysis of the positivity rate in IgE positive patients to inhalant allergens in Verona Hospital Laboratory during 2002-2003 165
A double-blind placebo-controlled study on the diagnostic accuracy of an electrodermal test in allergic subjects 163
Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma 159
Biologics for Eosinophilic Granulomatosis with Polyangiitis: one size does not fit all 155
Clinical response to biologicals for severe asthma: any relevance for sex in different age ranges? 154
Evaluation of asthma control in the pharmacy: an Italian cross-sectional study 153
Asthma under/misdiagnosis in primary care setting: an observational community-based study in Italy 152
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 151
Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis 151
Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved? 150
Periostin: The bone and beyond 150
Thunderstorm Asthma: A Critical Appraisal Based on Clinical Practice 149
Importance of Cardiopulmonary Exercise Testing amongst Subjects Recovering from COVID-19 149
Allergen-specific immunotherapy and COVID-19: What happened? 146
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 146
COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control 145
Biologics and global burden of asthma: A worldwide portrait and a call for action 144
Low‑dose anti‑IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance 144
Anaphylaxis and intimate behaviour 143
Residual Lung Function Impairment Is Associated with Hyperventilation in Patients Recovered from Hospitalised COVID-19: A Cross-Sectional Study 143
ALLERGY AND CORONAVIRUS DISEASE (COVID-19) INTERNATIONAL SURVEY: REAL-LIFE DATA FROM THE ALLERGY COMMUNITY DURING THE PANDEMIC 140
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic 139
Idiopathic hypereosinophilic syndromes and rare dysimmune conditions associated with hyper-eosinophilia in practice: An innovative multidisciplinary approach 138
Impatto socio-sanitario e livello del controllo delle patologie respiratorie croniche ostruttive e della rinite in Italia 138
Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase 136
Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective 135
Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia 135
Anaphylaxis and Coronavirus Disease 2019 vaccine: a danger relationship? 134
The potential role of local pharmacies to assess asthma control: an Italian cross-sectional study 134
Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach 132
Timing of response and long term efficacy of Omalizumab in non-clonal Mast Cell Activation Syndrome: A case series 132
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response 132
Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials 131
Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety 130
COPD prevalence in a north-eastern Italian general population 130
Multidisciplinary management in type 2 inflammatory disease 130
Profiling blood hypereosinophilia in patients on dupilumab treatment for respiratory conditions: a real-life snapshot 129
Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach? 125
Systemic Reactions After Hymenoptera Sting And Raised Serum Tryptase Strongly Suggest Clonal Mast Cells Disorders 122
What lies beyond Asthma Control Test: Suggestions for clinical practice 122
Eosinophilic Granulomatosis With Polyangiitis and Cardiac Involvement: A Case Report 121
Adherence to Intranasal Steroids in Chronic Rhinosinusitis with Nasal Polyposis Prior to and during Biologic Therapy: A Neglected Matter 120
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments 120
Trends and determinants of Emergency Room admissions for asthma: A retrospective evaluation in Northeast Italy 120
Uncontrolled Asthma: Unmet Needs in the Management of Patients 120
Omalizumab management beyond clinical trials: the added value of a network model 119
Relevance of TH2 markers in the assessment and therapeutic management of severe allergic asthma: A real-life perspective 118
Different aspects of severe asthma in real life: Role of Staphylococcus aureus enterotoxins and correlation to comorbidities and disease severity 118
Scombroid syndrome: it seems to be fish allergy but... it isn't 117
Anaphylaxis due to antiallergic and antiasthmatic biologics 116
Diagnosis, management and therapeutic options for eosinophilic esophagitis 116
Is hymenoptera venom allergy an occupational disease? 116
How much specific is the association between hymenoptera venom allergy and mastocytosis? 116
Potential benefit of omalizumab in respiratory diseases 114
A hierarchical cluster analysis of the psycological impact of the COVID-19 pandemic on Italian severe asthma patients 113
Wasp venom allergy screening with recombinant allergen testing. Diagnostic performance of rPol d 5 and rVes v 5 for differentiating sensitization to Vespula and Polistes subspecies 113
SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma 113
Asthma management among different specialists: results from a national Italian survey 113
Comment on: Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma: reply 113
Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort 113
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database 111
Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly 111
Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life 111
Low adherence to inhaled corticosteroids/long-acting β2-agonists and biologic treatment in severe asthmatics 111
Relevance of Smoking Habit in Severe Asthma Patients: Evidence from the Severe Asthma Network in Italy (SANI) Registry 110
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 110
The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors 109
Remission in Type 2 Inflammatory Diseases: Current Evidence, Unmet Needs, and Suggestions for Defining Remission in Chronic Rhinosinusitis with Nasal Polyps 109
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis 108
Diagnosis and Management of Allergic Rhinitis in Asthmatic Children 108
The degree of serological sensitization to cat allergen in patients with or without cat at home 107
Targeting eosinophils: severe asthma and beyond 107
IgE to staphylococcal enterotoxins are undetectable in sera from patients with nasal polyposis 106
How far from correct is the use of adrenaline auto-injectors? A survey in Italian patients 106
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 104
Extracellular Vesicles in Asthma: Intercellular Cross-Talk in TH2 Inflammation 102
Biologic Therapy in a Patient with Asthma and Nasal Polyps 102
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study 101
Oral health in asthmatic patients: a review: Asthma and its therapy may impact on oral health 101
One-year mepolizumab for Allergic bronchopulmonary aspergillosis: Focus on steroid sparing effect and markers of response 101
One year of mepolizumab. Efficacy and safety in real-life in Italy 100
Component resolved diagnosis (CRD): how much is it presently used by Italian allergists? 100
Serum periostin during omalizumab therapy in asthma: A tool for patient selection and treatment evaluation 99
Effect of α1 Antitrypsin Deficiency on Lung Volume Decline in Severe Asthmatic Patients Undergoing Biologic Therapy 99
Totale 13.784
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.873
article - articoli 64.718
book - libri 497
conference - conferenze 257
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 401
Totale 131.746
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202188 0 0 0 0 0 0 0 0 0 8 50 30
2021/2022712 85 172 19 45 16 14 15 48 50 13 51 184
2022/20231.855 139 158 190 266 179 421 31 108 222 15 86 40
2023/20241.347 52 95 121 169 115 283 89 63 20 59 192 89
2024/20253.211 160 182 152 447 124 100 119 255 499 237 264 672
2025/20269.863 689 642 726 1.745 2.663 668 881 579 782 488 0 0
Totale 18.746